COIRX Mutual Fund

COIRX Mutual Fund

NAV$19.28
See how much of COIRX you already own
Just $25 once·$99/mo·Download sample
X-ray my portfolio free

Fund Essentials - as of Jul 31, 2026

Net Assets
$49M
Expense Ratio
0.99%
Dividend Yield (Current)
3.28%
Holdings
86
Inception Date
Feb 1, 2019
Fund Family
Calvert
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO

Performance

YTD+7.93%
1 Year+7.36%
3 Year+10.49%
5 Year+0.48%
10 Year+7.05%

Asset Allocation

Stocks: 99.34%
Bonds: 0.66%
See how much of COIRX you already own
Your funds unpacked, overlap, fees and score, free on screen. The full report comes with FundXLS. Download sample.
X-ray my portfolio free

Top Holdings

View All →
TickerNameWeight
FBK:MIFinecobank2.44%
BAWG:ATBawag Group Ag Common Stock EUR2.16%
8697:TKJapan Exchange Group, Inc2.11%
DSCV:LNDiscoverie Group Plc2.06%
8876:JPRelo Group Inc2.00%
Top 10 Concentration: 20.39%Report Date: Jul 31, 2026
Download all 86 holdings for COIRX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Dividend Yield (Current)
3.28%
Latest Distribution
$0.17
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO

COIRX Mutual Fund Overview

COIRX Mutual Fund (Calvert International Opportunities Fund Class R6) is managed by Calvert with $48.9M in net assets. COIRX expense ratio is 0.99%, holding 86 positions across sectors including Financials, Industrials, Consumer Discretionary. Inception date: 2019-02-01.

COIRX performance shows a YTD return of 7.93%. The 1-year return is 7.36% and the 5-year return is 0.48%. COIRX dividend yield stands at 3.28%.

COIRX top holdings include Finecobank (2.4%), Bawag Group Ag Common Stock EUR (2.2%), Japan Exchange Group, Inc (2.1%), Discoverie Group Plc (2.1%), Relo Group Inc (2.0%). Go to all COIRX holdings, COIRX sectors, or COIRX dividends.

COIRX can be compared against other funds. Use COIRX overlap to find shared positions, or COIRX vs another fund for a side-by-side view. COIRX alternatives are available via the screener, along with tax-loss harvesting opportunities.